Your browser doesn't support javascript.
loading
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Carmagnani Pestana, Roberto; Moyers, Justin T; Roszik, Jason; Sen, Shiraj; Hong, David S; Naing, Aung; Herzog, Cynthia E; Fu, Siqing; Piha-Paul, Sarina A; Rodon, Jordi; Yap, Timothy A; Karp, Daniel D; Tsimberidou, Apostolia M; Pant, Shubham; Zarzour, Maria A; Ratan, Ravin; Ravi, Vinod; Benjamin, Robert S; Lazar, Alexander J; Wang, Wei-Lien; Daw, Najat; Gill, Jonathan B; Harrison, Douglas J; Lewis, Valerae O; Roland, Christina L; Patel, Shreyaskumar R; Livingston, J Andrew; Somaiah, Neeta; Ludwig, Joseph A; Conley, Anthony P; Hamerschlak, Nelson; Gorlick, Richard; Meric-Bernstam, Funda; Subbiah, Vivek.
Affiliation
  • Carmagnani Pestana R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Moyers JT; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Roszik J; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sen S; Department of Medicine, Division of Hematology and Oncology, The University of California, Irvine, Orange, California.
  • Hong DS; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Naing A; Sarah Cannon Research Institute, Nashville, Tennessee.
  • Herzog CE; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Fu S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Piha-Paul SA; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rodon J; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Yap TA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Karp DD; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Tsimberidou AM; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pant S; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Zarzour MA; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ratan R; Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Benjamin RS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lazar AJ; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang WL; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Daw N; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gill JB; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Harrison DJ; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lewis VO; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Roland CL; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Patel SR; Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Livingston JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Somaiah N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ludwig JA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Conley AP; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hamerschlak N; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gorlick R; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Meric-Bernstam F; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Subbiah V; Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res ; 29(9): 1708-1718, 2023 05 01.
Article in En | MEDLINE | ID: mdl-37058010
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Soft Tissue Neoplasms / Gastrointestinal Stromal Tumors Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Soft Tissue Neoplasms / Gastrointestinal Stromal Tumors Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2023 Document type: Article Country of publication: